|1.||Greinacher, Andreas: 11 articles (01/2014 - 10/2002)|
|2.||Greinacher, A: 9 articles (02/2010 - 08/2000)|
|3.||Warkentin, Theodore E: 8 articles (06/2008 - 09/2002)|
|4.||Eichler, P: 6 articles (11/2005 - 08/2000)|
|5.||Lubenow, N: 6 articles (11/2005 - 08/2000)|
|6.||Gruel, Yves: 4 articles (09/2008 - 04/2006)|
|7.||Deitcher, Steven R: 4 articles (04/2005 - 02/2002)|
|8.||Gajra, Ajeet: 3 articles (08/2008 - 05/2007)|
|9.||Lubenow, Norbert: 3 articles (11/2004 - 10/2002)|
|10.||Eichler, Petra: 3 articles (11/2004 - 04/2003)|
05/01/2009 - "A case of lepirudin-induced thrombocytopenia is reported. "
05/01/2009 - "Lepirudin-induced thrombocytopenia following subcutaneous administration."
05/01/2009 - "A 61-year-old white man with a history of thromboses and suspected HIT developed thrombocytopenia possibly associated with receiving two courses of subcutaneous lepirudin. "
11/01/2005 - "To assess efficacy and safety of lepirudin in patients with heparin-induced thrombocytopenia (HIT) in a prospective study (HAT-3) as well as in a combined analysis of all HAT study data. "
05/01/2004 - "A postmarketing, observational study, termed the Drug-Monitoring Program, evaluated lepirudin in over 1000 patients with heparin-induced thrombocytopenia in the setting of routine clinical practice. "
|2.||Renal Insufficiency (Renal Failure)
04/01/2002 - "However, because it is eliminated by the kidneys, the half-life of lepirudin may be substantially prolonged in patients with renal failure. "
05/01/2007 - "The half-life of lepirudin is prolonged in patients with renal insufficiency. "
02/01/2006 - "Lepirudin requires dosage adjustments in patients with renal insufficiency and has potential for antibody formation. "
12/15/2003 - "Recommended and actual lepirudin doses in patients with renal insufficiency."
07/01/2003 - "Despite lepirudin administration is not yet clearly precise for CPB procedure, its use seems adapted and safe in subjects without renal insufficiency but requiring precise coordination for anaesthesiological, surgical and biological teams."
12/01/2014 - "Lepirudin therapeutic index is narrow and so, overdosing can lead to catastrophic bleeding, whereas underdosing can result in clotting in the CPB tubing. "
09/01/2006 - "Overall, these results suggest that the recommended dose of lepirudin in patients with HIT is too high; the use of reduced doses may be safer with regard to bleeding risk and does not compromise antithrombotic efficacy."
09/01/2006 - "In contrast, mean lepirudin dose greater than 0.07 mg/kg/h, long duration of lepirudin treatment, and moderate to severe renal impairment were significant positive factors for major bleeding. "
09/01/2006 - "A retrospective observational analysis in 181 patients (median age, 67 years) with confirmed HIT treated in routine practice with lepirudin was performed to identify predictive factors for thrombotic and bleeding complications. "
11/01/2005 - "Major bleeding was more frequent in the lepirudin-treated patients (29.4% vs. 9.1%, P = 0.0148). "
05/01/2009 - "Thrombosis during lepirudin therapy: a case report."
08/01/2008 - "Lepirudin for treatment of acute thrombosis during pregnancy."
09/01/2006 - "On multivariate analysis, mean lepirudin dose was not a significant predictive factor for thrombosis. "
01/01/2005 - "Treatment of a woman with lupus pernio, thrombosis and cutaneous intolerance to heparins using lepirudin during pregnancy."
11/07/2003 - "[Biventricular thrombus resolution and antibody formation during lepirudin therapy. "
|5.||Venous Thrombosis (Deep-Vein Thrombosis)
09/01/1998 - "Preliminary studies in patients with deep vein thrombosis (DVT) suggest that lepirudin may be more effective than unfractionated heparin (UFH) at preventing pulmonary perfusion defects. "
05/01/1994 - "The aim of our study was to assess the pharmacokinetics, the results on the coagulation variables, and the safety of a recombinant hirudin (HBW 023) administered subcutaneously in patients suffering from deep vein thrombosis. "
05/01/1994 - "A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis."
05/01/1997 - "The aim of this multicentre, prospective, randomised, dose-ranging study was to compare the safety and efficacy of subcutaneous recombinant hirudin (HBW 023) against intravenous sodium heparin in acute lower limb deep venous thrombosis (DVT). "
05/01/1997 - "Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. "
|5.||Troponin T (T, Troponin)
|1.||Renal Dialysis (Hemodialysis)
|5.||Drug Therapy (Chemotherapy)